Compare EPR Properties (EPR) vs Eli Lilly And Co (LLY) Price & Performance

EPR Properties (EPR) trades at $54.08, down 2.15% today, with a bearish technical signal and oversold RSI suggesting potential reversal. The REIT maintains strong fundamentals with 91.41% gross margins and consistent dividend payments, though recent earnings showed a Q1 miss. Analyst consensus remains positive with a $65.50 price target, representing 21% upside from current levels.

EPR offers attractive income potential with a 6.5% dividend yield and diversified real estate portfolio, but faces headwinds from rising interest rates and mixed earnings performance. The stock's current valuation at 17.44 P/E appears reasonable, though technical weakness and negative cash flow projections for 2026 warrant caution for near-term investors.

Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.

Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.